Adiponectin ameliorates endotoxin-induced acute cardiac injury

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Watanabe, Yoshio ^a   Shibata, Rei ^a   Ouchi, Noriyuki ^a   Kambara, Takahiro ^a   Ohashi, Koji ^a   Jie, Li ^a   Inoue, Yoko ^a   Murohara, Toyoaki ^a   Komori, Kimihiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADIPONECTIN; CYTOKINE; ETANERCEPT; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDITIS; CONTROLLED STUDY; HEART INJURY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; GENETICS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; IMMUNOLOGY; KNOCKOUT MOUSE; MYOCARDITIS;

ADIPONECTIN; ANIMALS; CYTOKINES; HEART VENTRICLES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDITIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84907397464     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/382035     Document Type: Article

References (33)

1. D. C. Angus and R. S. Wax, "Epidemiology of sepsis: an update," Critical Care Medicine, vol. 29, no. 7, pp. S109-S116, 2001.
2. A. F. Suffredini, R. E. Fromm, M. M. Parker et al., "The cardiovascular response of normal humans to the administration of endotoxin," The New England Journal of Medicine, vol. 321, no. 5, pp. 280-287, 1989.
3. A. Kumar, C. Haery, and J. E. Parrillo, "Myocardial dysfunction in septic shock, Part I: clinical manifestation of cardiovascular dysfunction," Journal of Cardiothoracic and Vascular Anesthesia, vol. 15, no. 3, pp. 364-376, 2001.
4. J. E. Parrillo, M. M. Parker, C. Natanson et al., "Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy," Annals of Internal Medicine, vol. 113, no. 3, pp. 227-242, 1990.
5. C. Natanson, P. W. Eichenholz, R. L. Danner et al., "Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock," Journal of Experimental Medicine, vol. 169, no. 3, pp. 823-832, 1989.
6. T. Peng, X. Lu, M. Lei, G. W. Moe, and Q. Feng, "Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia," Cardiovascular Research, vol. 59, no. 4, pp. 893-900, 2003.
7. T. Peng, X. Lu, and Q. Feng, "Pivotal role of gp91phox-containing NADH oxidase in lipopolysaccharide-induced tumor necrosis factor-α expression and myocardial depression," Circulation, vol. 111, no. 13, pp. 1637-1644, 2005.
8. A. El-Solh, P. Sikka, E. Bozkanat, W. Jaafar, and J.Davies, "Morbid obesity in the medical ICU," Chest, vol. 120, no. 6, pp. 1989-1997, 2001.
9. M. Yaegashi, R. Jean, M. Zuriqat, S. Noack, and P. Homel, "Outcome of morbid obesity in the intensive care unit," Journal of Intensive Care Medicine, vol. 20, no. 3, pp. 147-154, 2005.
10. M. B. Bailey, D. L. Davenport, L. Procter, S. McKenzie, and H. D. Vargas, "Morbid obesity and diverticulitis: results fromthe ACS NSQIP dataset," Journal of the American College of Surgeons, vol. 217, pp. 874-880.e1, 2013.
11. R. S. Ahima, "Adipose tissue as an endocrine organ," Obesity, vol. 14, supplement 5, pp. 242S-249S, 2006.
12. C. J. Lyon, R. E. Law, and W. A. Hsueh, "Minireview: adiposity, inflammation, and atherogenesis," Endocrinology, vol. 144, no. 6, pp. 2195-2200, 2003.
13. V. Vachharajani and D. N. Granger, "Adipose tissue: amotor for the inflammation associated with obesity," IUBMB Life, vol. 61, no. 4, pp. 424-430, 2009.
14. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, "Adipokines in inflammation andmetabolic disease," Nature Reviews Immunology, vol. 11, no. 2, pp. 85-97, 2011.
15. K. Ohashi, R. Shibata, T. Murohara, and N. Ouchi, "Role of anti-inflammatory adipokines in obesity-related diseases," Trends in Endocrinology and Metabolism, vol. 25, no. 7, pp. 348-355, 2014.
16. R. Shibata, N. Ouchi, and T. Murohara, "Adiponectin and cardiovascular disease," Circulation Journal, vol. 73, no. 4, pp. 608-614, 2009.
17. R. Shibata, T. Murohara, and N. Ouchi, "Protective role of adiponectin in cardiovascular disease," Current Medicinal Chemistry, vol. 19, no. 32, pp. 5459-5466, 2012.
18. R. Shibata, K. Sato, D. R. Pimentel et al., "Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms," Nature Medicine, vol. 11, no. 10, pp. 1096-1103, 2005.
19. K. Kondo, R. Shibata, K. Unno et al., "Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model," Circulation: Cardiovascular Interventions, vol. 3, no. 2, pp. 166-173, 2010.
20. R. Shibata, N. Ouchi, M. Ito et al., "Adiponectin-mediated modulation of hypertrophic signals in the heart," Nature Medicine, vol. 10, no. 12, pp. 1384-1389, 2004.
21. S. Maruyama, R. Shibata, K. Ohashi et al., "Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt proteindependent mechanism," Journal of Biological Chemistry, vol. 286, no. 37, pp. 32790-32800, 2011.
22. S. Liu, T. Yin, X. Wei et al., "Downregulation of adiponectin induced by tumor necrosis factor α is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury," Critical Care Medicine, vol. 39, no. 8, pp. 1935-1943, 2011.
23. K. Drosatos, R. S. Khan, C. M. Trent et al., "Peroxisome proliferator-activated receptor-ã activation prevents sepsis-related cardiac dysfunction and mortality in mice," Circulation: Heart Failure, vol. 6, no. 3, pp. 550-562, 2013.
24. L. C. Casey, R. A. Balk, and R. C. Bone, "Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome," Annals of Internal Medicine, vol. 119, no. 8, pp. 771-778, 1993.
25. M. Sun, F. Dawood, W. Wen et al., "Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction," Circulation, vol. 110, no. 20, pp. 3221-3228, 2004.
26. T. Kadokami, C. Frye, B. Lemster, C. L. Wagner, A. M. Feldman, and C. F. McTiernan, "Anti-tumor necrosis factor-α antibody limits heart failure in a transgenic model," Circulation, vol. 104, no. 10, pp. 1094-1097, 2001.
27. T. Kubota, G. S. Bounoutas, M. Miyagishima et al., "Soluble tumor necrosis factor receptor abrogatesmyocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy," Circulation, vol. 101, no. 21, pp. 2518-2525, 2000.
28. T. Kadokami, C. F. McTiernan, T. Kubota et al., "Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression," The American Journal of Physiology: Heart and Circulatory Physiology, vol. 280, no. 5, pp. H2281-H2291, 2001.
29. N. Ouchi, S. Kihara, Y. Arita et al., "Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages," Circulation, vol. 103, no. 8, pp. 1057-1063, 2001.
30. M. Kumada, S. Kihara, N. Ouchi et al., "Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages," Circulation, vol. 109, no. 17, pp. 2046-2049, 2004.
31. A. Higuchi, K. Ohashi, S. Kihara, K. Walsh, and N. Ouchi, "Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-α expression," Circulation Research, vol. 104, no. 9, pp. 1058-1065, 2009.
32. V. Vachharajani, J. M. Russell, K. L. Scott et al., "Obesity exacerbates sepsis-induced inflammation and microvascular dysfunction inmouse brain," Microcirculation, vol. 12, no. 2, pp. 183-194, 2005.
33. G. Singer, K. Y. Stokes, S. Terao, and D. N. Granger, "Sepsis-induced intestinal microvascular and inflammatory responses in obese mice," Shock, vol. 31, no. 3, pp. 275-279, 2009.